Advanced Search
Display options
Filter resources
Text Availability
Article type
Publication date
Species
Language
Sex
Age
Showing 1 to 12 of 15 entries
Sorted by: Best Match Show Resources per page
Understanding pharmacogenomic testing and its role in medicine prescribing.

Nursing standard (Royal College of Nursing (Great Britain) : 1987)

Youssef E, Buck J, Wright DJ.
PMID: 32524796
Nurs Stand. 2020 Jul 08;35(7):55-60. doi: 10.7748/ns.2020.e11543. Epub 2020 Jun 11.

When making prescribing decisions, it is important for healthcare professionals to remember that individual patients may respond differently to medicines. For example, some patients may experience a therapeutic benefit while others may experience an adverse drug reaction. The aim...

Cite
Youssef E, Buck J, Wright DJ. Understanding pharmacogenomic testing and its role in medicine prescribing. Nurs Stand. 2020;35(7):55-60doi: 10.7748/ns.2020.e11543.
Youssef, E., Buck, J., & Wright, D. J. (2020). Understanding pharmacogenomic testing and its role in medicine prescribing. Nursing standard (Royal College of Nursing (Great Britain) : 1987), 35(7), 55-60. https://doi.org/10.7748/ns.2020.e11543
Youssef, Essra, et al. "Understanding pharmacogenomic testing and its role in medicine prescribing." Nursing standard (Royal College of Nursing (Great Britain) : 1987) vol. 35,7 (2020): 55-60. doi: https://doi.org/10.7748/ns.2020.e11543
Youssef E, Buck J, Wright DJ. Understanding pharmacogenomic testing and its role in medicine prescribing. Nurs Stand. 2020 Jul 08;35(7):55-60. doi: 10.7748/ns.2020.e11543. Epub 2020 Jun 11. PMID: 32524796.
Copy Download .nbib Format: NLM
Precision Medicine 2030.

Clinical pharmacology and therapeutics

Pacanowski M, Liu Q.
PMID: 31782136
Clin Pharmacol Ther. 2020 Jan;107(1):62-64. doi: 10.1002/cpt.1675. Epub 2019 Nov 28.

No abstract available.

Cite
Pacanowski M, Liu Q. Precision Medicine 2030. Clin Pharmacol Ther. 2019;107(1):62-64doi: 10.1002/cpt.1675.
Pacanowski, M., & Liu, Q. (2020). Precision Medicine 2030. Clinical pharmacology and therapeutics, 107(1), 62-64. https://doi.org/10.1002/cpt.1675
Pacanowski, Michael, and Liu, Qi. "Precision Medicine 2030." Clinical pharmacology and therapeutics vol. 107,1 (2020): 62-64. doi: https://doi.org/10.1002/cpt.1675
Pacanowski M, Liu Q. Precision Medicine 2030. Clin Pharmacol Ther. 2020 Jan;107(1):62-64. doi: 10.1002/cpt.1675. Epub 2019 Nov 28. PMID: 31782136.
Copy Download .nbib Format: NLM
Creating reproducible pharmacogenomic analysis pipelines.

Scientific data

Mammoliti A, Smirnov P, Safikhani Z, Ba-Alawi W, Haibe-Kains B.
PMID: 31481707
Sci Data. 2019 Sep 03;6(1):166. doi: 10.1038/s41597-019-0174-7.

The field of pharmacogenomics presents great challenges for researchers that are willing to make their studies reproducible and shareable. This is attributed to the generation of large volumes of high-throughput multimodal data, and the lack of standardized workflows that...

Cite
Mammoliti A, Smirnov P, Safikhani Z, et al. Creating reproducible pharmacogenomic analysis pipelines. Sci Data. 2019;6(1):166doi: 10.1038/s41597-019-0174-7.
Mammoliti, A., Smirnov, P., Safikhani, Z., Ba-Alawi, W., & Haibe-Kains, B. (2019). Creating reproducible pharmacogenomic analysis pipelines. Scientific data, 6(1), 166. https://doi.org/10.1038/s41597-019-0174-7
Mammoliti, Anthony, et al. "Creating reproducible pharmacogenomic analysis pipelines." Scientific data vol. 6,1 (2019): 166. doi: https://doi.org/10.1038/s41597-019-0174-7
Mammoliti A, Smirnov P, Safikhani Z, Ba-Alawi W, Haibe-Kains B. Creating reproducible pharmacogenomic analysis pipelines. Sci Data. 2019 Sep 03;6(1):166. doi: 10.1038/s41597-019-0174-7. PMID: 31481707; PMCID: PMC6722117.
Copy Download .nbib Format: NLM
Are patients willing to incur out-of-pocket costs for pharmacogenomic testing?.

The pharmacogenomics journal

Bielinski SJ, St Sauver JL, Olson JE, Wieland ML, Vitek CR, Bell EJ, Mc Gree ME, Jacobson DJ, McCormick JB, Takahashi PY, Black JL, Caraballo PJ, Sharp RR, Beebe TJ, Weinshilboum RM, Wang L, Roger VL.
PMID: 27779246
Pharmacogenomics J. 2017 Jan;17(1):1-3. doi: 10.1038/tpj.2016.72. Epub 2016 Oct 25.

No abstract available.

Cite
Bielinski SJ, St Sauver JL, Olson JE, et al. Are patients willing to incur out-of-pocket costs for pharmacogenomic testing?. Pharmacogenomics J. 2016;17(1):1-3doi: 10.1038/tpj.2016.72.
Bielinski, S. J., St Sauver, J. L., Olson, J. E., Wieland, M. L., Vitek, C. R., Bell, E. J., Mc Gree, M. E., Jacobson, D. J., McCormick, J. B., Takahashi, P. Y., Black, J. L., Caraballo, P. J., Sharp, R. R., Beebe, T. J., Weinshilboum, R. M., Wang, L., & Roger, V. L. (2017). Are patients willing to incur out-of-pocket costs for pharmacogenomic testing?. The pharmacogenomics journal, 17(1), 1-3. https://doi.org/10.1038/tpj.2016.72
Bielinski, S J, et al. "Are patients willing to incur out-of-pocket costs for pharmacogenomic testing?." The pharmacogenomics journal vol. 17,1 (2017): 1-3. doi: https://doi.org/10.1038/tpj.2016.72
Bielinski SJ, St Sauver JL, Olson JE, Wieland ML, Vitek CR, Bell EJ, Mc Gree ME, Jacobson DJ, McCormick JB, Takahashi PY, Black JL, Caraballo PJ, Sharp RR, Beebe TJ, Weinshilboum RM, Wang L, Roger VL. Are patients willing to incur out-of-pocket costs for pharmacogenomic testing?. Pharmacogenomics J. 2017 Jan;17(1):1-3. doi: 10.1038/tpj.2016.72. Epub 2016 Oct 25. PMID: 27779246; PMCID: PMC5310981.
Copy Download .nbib Format: NLM
Rare disease prevention and treatment: the need for a level playing field.

Pharmacogenomics

Hughes DA, Plumpton CO.
PMID: 29327657
Pharmacogenomics. 2018 Feb;19(3):243-247. doi: 10.2217/pgs-2017-0300. Epub 2018 Jan 12.

Pharmacogenetic tests are being used increasingly to prevent rare and potentially life-threatening adverse drug reactions. For many tests, however, cost-effectiveness is hard to demonstrate, and with the exception of a few cases, widespread implementation remains a distant prospect. Many...

Cite
Hughes DA, Plumpton CO. Rare disease prevention and treatment: the need for a level playing field. Pharmacogenomics. 2018;19(3):243-247doi: 10.2217/pgs-2017-0300.
Hughes, D. A., & Plumpton, C. O. (2018). Rare disease prevention and treatment: the need for a level playing field. Pharmacogenomics, 19(3), 243-247. https://doi.org/10.2217/pgs-2017-0300
Hughes, Dyfrig A, and Plumpton, Catrin O. "Rare disease prevention and treatment: the need for a level playing field." Pharmacogenomics vol. 19,3 (2018): 243-247. doi: https://doi.org/10.2217/pgs-2017-0300
Hughes DA, Plumpton CO. Rare disease prevention and treatment: the need for a level playing field. Pharmacogenomics. 2018 Feb;19(3):243-247. doi: 10.2217/pgs-2017-0300. Epub 2018 Jan 12. PMID: 29327657.
Copy Download .nbib Format: NLM
Pharmacogenetic Testing-An Unfulfilled Promise.

American family physician

Campos-Outcalt DE.
PMID: 26447437
Am Fam Physician. 2015 Oct 01;92(7):558-9.

No abstract available.

Cite
Campos-Outcalt DE. Pharmacogenetic Testing-An Unfulfilled Promise. Am Fam Physician. 2015;92(7):558-9
Campos-Outcalt, D. E. (2015). Pharmacogenetic Testing-An Unfulfilled Promise. American family physician, 92(7), 558-9.
Campos-Outcalt, Doug E. "Pharmacogenetic Testing-An Unfulfilled Promise." American family physician vol. 92,7 (2015): 558-9.
Campos-Outcalt DE. Pharmacogenetic Testing-An Unfulfilled Promise. Am Fam Physician. 2015 Oct 01;92(7):558-9. PMID: 26447437.
Copy Download .nbib Format: NLM
Pharmacogenetic testing through the direct-to-consumer genetic testing company 23andMe.

BMC medical genomics

Lu M, Lewis CM, Traylor M.
PMID: 28629370
BMC Med Genomics. 2017 Jun 19;10(1):47. doi: 10.1186/s12920-017-0283-0.

BACKGROUND: Rapid advances in scientific research have led to an increase in public awareness of genetic testing and pharmacogenetics. Direct-to-consumer (DTC) genetic testing companies, such as 23andMe, allow consumers to access their genetic information directly through an online service...

Cite
Lu M, Lewis CM, Traylor M. Pharmacogenetic testing through the direct-to-consumer genetic testing company 23andMe. BMC Med Genomics. 2017;10(1):47doi: 10.1186/s12920-017-0283-0.
Lu, M., Lewis, C. M., & Traylor, M. (2017). Pharmacogenetic testing through the direct-to-consumer genetic testing company 23andMe. BMC medical genomics, 10(1), 47. https://doi.org/10.1186/s12920-017-0283-0
Lu, Mengfei, et al. "Pharmacogenetic testing through the direct-to-consumer genetic testing company 23andMe." BMC medical genomics vol. 10,1 (2017): 47. doi: https://doi.org/10.1186/s12920-017-0283-0
Lu M, Lewis CM, Traylor M. Pharmacogenetic testing through the direct-to-consumer genetic testing company 23andMe. BMC Med Genomics. 2017 Jun 19;10(1):47. doi: 10.1186/s12920-017-0283-0. PMID: 28629370; PMCID: PMC5477417.
Copy Download .nbib Format: NLM
Pharmacogenetic testing in primary care.

The Nurse practitioner

Parve J, Carlile J, Parve J.
PMID: 31568030
Nurse Pract. 2019 Oct;44(10):44-49. doi: 10.1097/01.NPR.0000580780.66980.85.

The purpose of pharmacogenetic testing is to determine the risk of adverse reactions and/or likelihood of a medication's effectiveness. Pharmacogenetic testing can assist primary care providers in tailoring treatment according to a patient's genetic traits and his or her...

Cite
Parve J, Carlile J, Parve J. Pharmacogenetic testing in primary care. Nurse Pract. 2019;44(10):44-49doi: 10.1097/01.NPR.0000580780.66980.85.
Parve, J., Carlile, J., & Parve, J. (2019). Pharmacogenetic testing in primary care. The Nurse practitioner, 44(10), 44-49. https://doi.org/10.1097/01.NPR.0000580780.66980.85
Parve, Julie, et al. "Pharmacogenetic testing in primary care." The Nurse practitioner vol. 44,10 (2019): 44-49. doi: https://doi.org/10.1097/01.NPR.0000580780.66980.85
Parve J, Carlile J, Parve J. Pharmacogenetic testing in primary care. Nurse Pract. 2019 Oct;44(10):44-49. doi: 10.1097/01.NPR.0000580780.66980.85. PMID: 31568030.
Copy Download .nbib Format: NLM
Bringing Personalized Medicine to a PACT Program: A Quality Improvement Project.

Journal of the American Psychiatric Nurses Association

Conley VM, Daack-Hirsch S, Halbmaier K, Shaw L.
PMID: 30688546
J Am Psychiatr Nurses Assoc. 2020 Jan/Feb;26(1):77-85. doi: 10.1177/1078390319826687. Epub 2019 Jan 28.

No abstract available.

Cite
Conley VM, Daack-Hirsch S, Halbmaier K, et al. Bringing Personalized Medicine to a PACT Program: A Quality Improvement Project. J Am Psychiatr Nurses Assoc. 2019;26(1):77-85doi: 10.1177/1078390319826687.
Conley, V. M., Daack-Hirsch, S., Halbmaier, K., & Shaw, L. (2020). Bringing Personalized Medicine to a PACT Program: A Quality Improvement Project. Journal of the American Psychiatric Nurses Association, 26(1), 77-85. https://doi.org/10.1177/1078390319826687
Conley, Virginia M, et al. "Bringing Personalized Medicine to a PACT Program: A Quality Improvement Project." Journal of the American Psychiatric Nurses Association vol. 26,1 (2020): 77-85. doi: https://doi.org/10.1177/1078390319826687
Conley VM, Daack-Hirsch S, Halbmaier K, Shaw L. Bringing Personalized Medicine to a PACT Program: A Quality Improvement Project. J Am Psychiatr Nurses Assoc. 2020 Jan/Feb;26(1):77-85. doi: 10.1177/1078390319826687. Epub 2019 Jan 28. PMID: 30688546.
Copy Download .nbib Format: NLM
Who Believes They Are "Just Average": Informing the Treatment of Individual Patients Using Population Data.

Clinical pharmacology and therapeutics

Leeder JS.
PMID: 31509232
Clin Pharmacol Ther. 2019 Nov;106(5):939-941. doi: 10.1002/cpt.1612. Epub 2019 Sep 11.

No abstract available.

Cite
Leeder JS. Who Believes They Are "Just Average": Informing the Treatment of Individual Patients Using Population Data. Clin Pharmacol Ther. 2019;106(5):939-941doi: 10.1002/cpt.1612.
Leeder, J. S. (2019). Who Believes They Are "Just Average": Informing the Treatment of Individual Patients Using Population Data. Clinical pharmacology and therapeutics, 106(5), 939-941. https://doi.org/10.1002/cpt.1612
Leeder, J Steven. "Who Believes They Are "Just Average": Informing the Treatment of Individual Patients Using Population Data." Clinical pharmacology and therapeutics vol. 106,5 (2019): 939-941. doi: https://doi.org/10.1002/cpt.1612
Leeder JS. Who Believes They Are "Just Average": Informing the Treatment of Individual Patients Using Population Data. Clin Pharmacol Ther. 2019 Nov;106(5):939-941. doi: 10.1002/cpt.1612. Epub 2019 Sep 11. PMID: 31509232; PMCID: PMC6777993.
Copy Download .nbib Format: NLM
The coming-of-age of pharmacogenetic testing in clinical psychiatry.

Psychiatry and clinical neurosciences

Yoshida K, Müller DJ, Kennedy JL.
PMID: 31045316
Psychiatry Clin Neurosci. 2019 May;73(5):203. doi: 10.1111/pcn.12832.

No abstract available.

Cite
Yoshida K, Müller DJ, Kennedy JL. The coming-of-age of pharmacogenetic testing in clinical psychiatry. Psychiatry Clin Neurosci. 2019;73(5):203doi: 10.1111/pcn.12832.
Yoshida, K., Müller, D. J., & Kennedy, J. L. (2019). The coming-of-age of pharmacogenetic testing in clinical psychiatry. Psychiatry and clinical neurosciences, 73(5), 203. https://doi.org/10.1111/pcn.12832
Yoshida, Kazunari, et al. "The coming-of-age of pharmacogenetic testing in clinical psychiatry." Psychiatry and clinical neurosciences vol. 73,5 (2019): 203. doi: https://doi.org/10.1111/pcn.12832
Yoshida K, Müller DJ, Kennedy JL. The coming-of-age of pharmacogenetic testing in clinical psychiatry. Psychiatry Clin Neurosci. 2019 May;73(5):203. doi: 10.1111/pcn.12832. PMID: 31045316.
Copy Download .nbib Format: NLM
Clinical Implications of Pharmacogenomic Testing in the Real World-Insights From a Pediatric Program.

JAMA network open

Chanfreau-Coffinier C.
PMID: 34037737
JAMA Netw Open. 2021 May 03;4(5):e2110467. doi: 10.1001/jamanetworkopen.2021.10467.

No abstract available.

Cite
Chanfreau-Coffinier C. Clinical Implications of Pharmacogenomic Testing in the Real World-Insights From a Pediatric Program. JAMA Netw Open. 2021;4(5):e2110467doi: 10.1001/jamanetworkopen.2021.10467.
Chanfreau-Coffinier, C. (2021). Clinical Implications of Pharmacogenomic Testing in the Real World-Insights From a Pediatric Program. JAMA network open, 4(5), e2110467. https://doi.org/10.1001/jamanetworkopen.2021.10467
Chanfreau-Coffinier, Catherine. "Clinical Implications of Pharmacogenomic Testing in the Real World-Insights From a Pediatric Program." JAMA network open vol. 4,5 (2021): e2110467. doi: https://doi.org/10.1001/jamanetworkopen.2021.10467
Chanfreau-Coffinier C. Clinical Implications of Pharmacogenomic Testing in the Real World-Insights From a Pediatric Program. JAMA Netw Open. 2021 May 03;4(5):e2110467. doi: 10.1001/jamanetworkopen.2021.10467. PMID: 34037737.
Copy Download .nbib Format: NLM
Showing 1 to 12 of 15 entries